INTRODUCTION {#S1}
============

Inturned (INTU) is a tissue-specific planar cell polarity (PCP) effector. It mediates the polarity cues set up by the core PCP components in *Drosophila* and vertebrate animals ^[@R1]^. During vertebrate morphogenesis, INTU also exerts prominent functions in primary cilia formation. Disrupting the *Intu* gene in mice can cause defects in neural tube formation, limb patterning, and hair follicle morphogenesis, all of which are associated with impaired cilia formation or function ^[@R2]--[@R6]^. Mechanistically, INTU forms a molecular module with the other two PCP effectors, Fuzzy (FUZ) and WDPCP, to facilitate the assembly of intraflagellar transport A (IFT-A) peripheral proteins into the IFT-A complex to facilitate cilia formation during vertebrate morphogenesis ^[@R7]^. Because of their prominent functions in PCP and ciliogenesis, these PCP effectors are recognized as [c]{.ul}ilia and [plan]{.ul}ar polarity [e]{.ul}ffectors (CPLANEs). However, their roles in tissue homeostasis are unclear.

Basal cell carcinoma (BCC) of the skin is the most common malignancy in the United States, with more than 2.8 million new diagnoses annually. BCC originates from epidermal keratinocytes and is caused predominantly by loss-of-function mutations in the patched 1 (*PTCH1*) ^[@R8],\ [@R9]^ or gain-of-function mutations in the smoothened (*SMO*) gene ^[@R10]^, which encodes upstream transmembrane components of the hedgehog (Hh) signaling pathway. Oncogenic mutations in *PTCH1* or *SMO* ultimately lead to uncontrolled activation of the glioma-associated oncogene (Gli) transcription factors, thus, the Hh signaling pathway ^[@R11]^.

The activation of the Hh signaling pathway is dependent on the primary cilium, a cellular organelle that is essential for the translocation of Hh pathway components and the subsequent activation of the Hh target genes, such as *Gli1* and *Ptch1* ^[@R12],\ [@R13]^. The functional importance of primary cilia for the Hh signaling pathway is well-established during both morphogenesis ^[@R13]--[@R15]^ and the formation of Hh-dependent tumors, such as medulloblastoma ^[@R16]^ and BCC ^[@R17]^.

To gain insight into the function of the CPLANEs during mammalian tissue homeostasis, we explored the functions of INTU in the context of BCC formation. We found that the *INTU* gene is aberrantly upregulated in human BCC specimens and that genetically ablating the endogenous *Intu* in a BCC mouse model blocked BCC formation, likely upstream of the activation of Gli transcription factors. These observations suggest that INTU, which is essential for ciliogenesis, plays a permissive role during the development of BCC.

RESULTS {#S2}
=======

*INTU* is upregulated in human BCC {#S3}
----------------------------------

To determine whether INTU is involved in epidermal homeostasis, we constructed a tissue microarray (TMA) comprised of healthy human skin, BCC, and squamous cell carcinoma (SCC) specimens ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}), and examined the transcriptional levels of the endogenous *INTU* gene by *in situ* hybridization. In healthy adult epidermis, *INTU* is predominantly expressed in interfollicular and follicular epidermal keratinocytes at a relatively modest level in comparison to embryonic skin ([Figure 1a and b](#F1){ref-type="fig"} and [Supplementary Figure 1b](#SD1){ref-type="supplementary-material"}). Strikingly, *INTU* expression was markedly elevated in BCC tumors (n = 19, *P* \< 0.05), but not in SCCs (n = 3), when compared to healthy adult skins (n = 3) ([Figure 1a and b](#F1){ref-type="fig"}). As expected, the transcription level of *PTCH1*, an Hh responsive genes, was also significantly elevated in BCC (*P* \< 0.001), but not SCC, a type of keratinocyte carcinoma that is not dependent on Hh signaling ([Figure 1a and c](#F1){ref-type="fig"}). *GLI1*, another Hh-responsive gene, exhibited a similar trend ([Figure 1a and d](#F1){ref-type="fig"}). In contrast, the level of *SMO*, which is not an Hh responsive gene, was unchanged ([Figure 1a and e](#F1){ref-type="fig"}). Moreover, the relative expression levels of *INTU* correlated with that of *PTCH1 (*Spearman r *=* 0.784*, P* \< 0.001) or *GLI1* (Spearman r = 0.858, *P* \< 0.001), but not with *SMO* ([Supplementary Figure 2a -- c](#SD1){ref-type="supplementary-material"}), suggesting that elevated level of *INTU* is associated with activation of the Hh signaling pathway in human skin.

Human BCCs comprise abundant ciliated keratinocytes {#S4}
---------------------------------------------------

It was reported that the primary cilia were frequently observed in BCC ^[@R17]^. To determine the prevalence of ciliated cells in human BCC, we evaluated the abundance of primary cilia in the same cohort of human skin specimens described above by immunofluorescence labeling. A significantly increased proportion (38.5 ± 13.3%) of BCC cells possesses a primary cilium in comparison to keratinocytes (2.5 ± 2.2%) in healthy skins or SCCs (2.4 ± 0.6%) ([Figure 1f and g](#F1){ref-type="fig"}, *P* \< 0.001), suggesting that the primary cilium may be a biomarker for BCC. Moreover, the abundance of ciliated cells also appeared correlated with the relative expression levels of *INTU* (Spearman r = 0.668, *P* \< 0.001, [Supplementary Figure 2d](#SD1){ref-type="supplementary-material"}). This observation suggested that the ciliogenic program is likely upregulated in BCC cells, which may be related to the elevated levels of *INTU* and the activated Hh signaling pathway.

*Intu* is essential for BCC formation {#S5}
-------------------------------------

INTU is essential for primary cilia formation and the activation of the Hh signaling pathway during skin morphogenesis ^[@R6]^. Elevated *INTU* expression, along with increased primary cilia formation and the aberrant activation of the Hh pathway, in BCC suggests that INTU may be functionally required for BCC formation. To test this idea, we engineered a BCC mouse model (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^*), which permits the simultaneous expression of an oncogenic mutant SmoM2 (*SmoM2^cond^*) and the ablation of the endogenous *Intu* locus (*Intu^flox/flox^*) through tamoxifen-induced activation of Cre recombinase in keratinocytes.

Initial tamoxifen treatment was carried out on 3-week old littermates. By five weeks, control mice that were heterozygous for the conditional allele of *Intu* (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^*) started to exhibit signs of various skin abnormalities, including hair loss, scaly skin, bumpy tails, and crumpled ears (data not shown). By 10 weeks, these skin phenotypes exacerbated and progressed to extensive skin erosion ([Figure 2a and b](#F2){ref-type="fig"}), thus, the control mice had to be euthanized. Histologically, dorsal skins of control mice revealed remarkable downward growth of hyperplastic keratinocytes ([Figure 2b](#F2){ref-type="fig"}). Consistent with previous reports ^[@R17]--[@R19]^, these cells exhibited features of human BCC, such as basaloid appearance, high nuclear to cytoplasmic ratio, and palisading nuclei ([Supplementary Figure 3a](#SD1){ref-type="supplementary-material"}). Immunofluorescence labeling confirmed that these cells coexpressed KRT14 and KRT17 ([Supplementary Figure 3b](#SD1){ref-type="supplementary-material"}), which is characteristic of BCC. Moreover, these BCC-like cells were positive for yellow fluorescence protein (YFP, [Figure 2c](#F2){ref-type="fig"}, upper and middle panels), which was coexpressed with SmoM2 as a fusion protein, thereby confirming that they were indeed derived from cells expressing SmoM2. Overall, these BCC-like lesions were reminiscent of human BCC. *In situ* hybridization confirmed that the endogenous *Intu* is abundantly expressed in these lesions ([Figure 2c](#F2){ref-type="fig"}).

In contrast, littermates homozygous for the conditional allele of *Intu* (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^*) did not show gross signs of BCC formation even by 22 weeks (or 154 days) after tamoxifen induction ([Figure 2a and b](#F2){ref-type="fig"} upper panels). Thus, disease-free survival of these mutant mice homozygous for *Intu* was significantly different than that of the control littermates (Logrank test *P* \< 0.0001, [Figure 2a](#F2){ref-type="fig"}). Histologically, the dorsal skins of homozygous mice exhibited rather mild hyperplasia and focal dysplasia ([Figure 2b](#F2){ref-type="fig"}, lower panels, arrow). YFP and KRT14 staining confirmed that keratinocytes of these mice expressed oncogenic *SmoM2* ([Figure 2c](#F2){ref-type="fig"}), whereas *in situ* hybridization demonstrated markedly diminished expression of *Intu* ([Figure 2c](#F2){ref-type="fig"}, lower panels), suggesting that *Intu* is required for the formation of oncogenic SmoM2-driven BCC.

Histologically, *Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^* mice exhibited consistently thinner interfollicular epidermis (IFE) in comparison to controls (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^*) ([Figure 2d](#F2){ref-type="fig"}, *P* \< 0.001). The thickness of IFE of BCC mouse models homozygous for *Intu* conditional allele remained constant up to 22 weeks after tamoxifen induction ([Figure 2d](#F2){ref-type="fig"}), suggesting genetically ablating *Intu* blocked, rather than delayed, BCC formation.

Moreover, the epidermis of *Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^* mice maintained normal KRT17 expressing pattern ([Supplementary Figure 3b](#SD1){ref-type="supplementary-material"}). BrdU labeling demonstrated that *Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^* skins harbored substantially more proliferating keratinocytes (KRT14-positive) than those of *Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^* mice (7.06 ± 0.49% vs 1.61 ± 0.41%, [Figure 2e](#F2){ref-type="fig"} and [Supplementary Figure 3c](#SD1){ref-type="supplementary-material"}). Taken together, these data demonstrated that genetically ablating *Intu* in the epidermis can protect mice from developing BCC-like lesions induced by the oncogenic SmoM2, suggesting that *Intu* plays a permissive role during BCC formation.

*Intu* is required for primary cilia formation in BCC {#S6}
-----------------------------------------------------

Primary cilia are abundant in human BCC ([Figure 1f and g](#F1){ref-type="fig"}) and are essential for Hh signaling. Therefore, it was speculated that cells in the BCC-like lesions in control mice are likely to be ciliated. Indeed, BCC-like lesions in *Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^* mice contained abundant ciliated keratinocytes (34.9 ± 6.7%, [Figure 3a](#F3){ref-type="fig"}), at a proportion similar to what was observed in human BCC (38.5 ± 13.3%, [Figure 1g](#F1){ref-type="fig"}). These findings not only suggest that the *SmoM2* mouse models are able to recapitulate cellular features of human BCC, but also suggest that upregulated cilia formation is an intrinsic feature of BCC.

Given the essential role of INTU in ciliogenesis, particularly in epidermal keratinocytes ^[@R6]^, we postulated that disrupting *Intu* might block BCC formation through impairing ciliogenesis. Indeed, homozygous *Intu* mutants (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^*) contained few ciliated epidermal keratinocytes (8.8 ± 1.4%), reminiscent of those not expressing *SmoM2* (9.4 ± 1.1%, *Krt14-Cre^ERT^;Intu^+/flox^*, [Figure 3a](#F3){ref-type="fig"}). These observations suggested that *Intu* might be required for BCC formation through facilitating ciliogenesis.

*Intu* is required for the activation of Hh signaling in BCC *in vivo* {#S7}
----------------------------------------------------------------------

Unrestricted activation of Hh signaling is the primary molecular driver for BCC. To determine whether *Intu* is required for the activation of the Hh signaling pathway during BCC formation, we examined Hh target genes (*Gli1* and *Ptch1*) in the SmoM2-driven BCC mouse models. *In situ* hybridization demonstrated that *Gli1* and *Ptch1* transcripts were markedly elevated in BCC-like lesions of control mice (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^*), but attenuated in homozygous *Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^* mice ([Figure 3b](#F3){ref-type="fig"}). In response to Hh pathway activation, canonical Wnt signaling is also activated in BCC. Indeed, nuclear LEF1, a marker for activated Wnt signaling, was expressed in cells of the BCC-like lesions of control (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^*) mice, but nearly undetectable in the skin of homozygous (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^*) mice, except in dermal papilla (DP) cells ([Figure 3c](#F3){ref-type="fig"}). These data suggest that *Intu* is required for the activation of the Hh signaling pathway during the development of *SmoM2*-driven BCC *in vivo*.

*Intu* is required for SmoM2-mediated Hh pathway activation in keratinocytes *in vitro* {#S8}
---------------------------------------------------------------------------------------

To further determine whether *Intu* is required for Hh pathway activation ensuing the expression of oncogenic *Smo* gene, we examined the expression of Hh target genes in primary keratinocytes harboring the inducible *SmoM2* allele. Five days after 4-OH tamoxifen induction, *Gli1* transcription was robustly upregulated in keratinocytes isolated from *Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^* mice in comparison to those isolated from control mice (*SmoM2^cond^;Intu^+/flox^*) ([Figure 4a](#F4){ref-type="fig"}). Whereas such induction was essentially abolished in cells isolated from mice homozygous for the conditional *Intu* allele (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^*) (*P* \< 0.05, [Figure 4a](#F4){ref-type="fig"}). Quantification of the transcriptional levels of *Intu* confirmed that the attenuated induction of *Gli1* was indeed associated with diminished levels of *Intu* ([Figure 4a](#F4){ref-type="fig"}). These findings suggest that *Intu* is required for keratinocyte to active the Hh signaling pathway in response to the expression of oncogenic *SmoM2*.

To determine whether the Hh phenotype of *Intu*-deficient keratinocytes is corroborated with impaired ciliogenesis, we examined the primary cilia by immunofluorescence. In 4-OH tamoxifen activated control cells (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^*, left, indicated by \*), *SmoM2* was activated as demonstrated by YFP. Primary cilium was readily detectable in 49.9 ± 2.8% control cells ([Figure 4b -- c](#F4){ref-type="fig"}). Moreover, SmoM2 appeared enriched at the primary cilium such that triple fluorescence labeling makes the cilium appear white ([Figure 4b](#F4){ref-type="fig"}, indicated by an arrow head). In contrast, in keratinocytes homozygous for the conditional allele of *Intu* (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^*), 4-OH tamoxifen activated the expression of SmoM2, as demonstrated by YFP expression ([Figure 4b](#F4){ref-type="fig"}, right, indicated by \*), but the formation of primary cilium was only observed in 25.8 ± 1.7% cells (*P* \< 0.05, [Figure 4c](#F4){ref-type="fig"}). Interestingly, primary cilia formation ([Figure 4b](#F4){ref-type="fig"}, right, indicated by an arrow) appeared unaffected in *Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^* or *Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^* cells that did not undergo Cre-mediated recombination, as judged by the lack of YFP expression (42.3 ± 8.9% and 47.1 ± 8.8%, respectively) ([Figure 4c](#F4){ref-type="fig"}). The ciliated *Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^* cells ([Figure 4b](#F4){ref-type="fig"}, right, indicated by p) presumably retained the endogenous *Intu* due to insufficient Cre-mediated recombination. These results suggested that *Intu* is essential for primary cilia formation irrespective of the expression of oncogenic *SmoM2*.

In summary, these *in vitro* experiments suggested that *Intu* is a key component of both ciliogenesis and the *SmoM2*-activated oncogenic Hh signaling.

*Intu* acts upstream of the Gli transcription factors {#S9}
-----------------------------------------------------

Data obtained so far in BCC was in line with prior findings that *Intu* is required for Hh pathway activation at the level of primary cilia. To examine whether *Intu* is also involved in the activation of the Hh signaling downstream of primary cilia, we examined Hh pathway in mouse embryonic fibroblasts (MEFs) that readily form primary cilia after serum starvation and respond to Hh pathway activation. First, we found that *Intu*^−/−^ MEFs exhibited strong primary cilia phenotypes such that ciliogenesis was almost completely suppressed (0.52 ± 0.53%) when compared with wild type MEFs (61.2 ± 1.9%) (*P* \< 0.001, [Fig. 5a](#F5){ref-type="fig"}). Moreover, the Smo Agonist (SAG)-mediated Hh pathway activation was severely attenuated in *Intu*^−/−^ MEFs in comparison to control wild type MEFs, as determined by the processing of full-length GLI3 (GLI3-FL) to GLI3 repressor (GLI3-R) ([Figure 5b](#F5){ref-type="fig"}), as well as the transcription levels of *Gli1* and *Ptch1* ([Figure 5c -- d](#F5){ref-type="fig"}, columns indicated by V). These results suggest that *Intu* is required for Smo-mediated Hh pathway activation.

To determine whether *Intu* is also involved in the molecular signaling machinery downstream of Smo, we used plasmids expressing inactive full-length Gli2 (Gli2-FL) and a constitutively active Gli2 (Gli2\_ Δ1-413 or Gli2ΔN) to rescue the Hh pathway in *Intu*^−/−^ MEFs. First, Gli2ΔN, but not Gli2-FL, consistently elicited Hh pathway activation in wild type and *Intu*^−/−^ MEFs, as determined by *Gli1* and *Ptch1* transcription ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}, and [Figure 5c -- d](#F5){ref-type="fig"}, open bars), suggesting that INTU functions upstream of GLI2 and is dispensable for Gli2ΔN-induced Hh pathway activation. When this experiment was conducted in conjunction with SAG, Gli2ΔN was unable to further activate Hh signaling in *Intu*^−/−^ MEFs, as determined by *Gli* and *Ptch1* transcription ([Figure 5c -- d](#F5){ref-type="fig"}, solid bars). This result conforms to the prior findings that *Intu* is required for SMO activation. The overexpression of Gli2-FL and Gli2ΔN was robust as confirmed in [Figure 5e](#F5){ref-type="fig"}. Collectively, these findings suggested that INTU acts upstream of Gli2 to facilitate oncogenic SMO-mediated Hh pathway activation.

To further determine whether elevated INTU levels might be sufficient to drive ciliogenesis and Hh pathway activation, we overexpressed mouse *Intu* that was fused with GFP (*mIntu*) ^[@R5]^ in wild type MEFs. *Intu* was robustly overexpressed in MEFs ([Figure 5f -- g](#F5){ref-type="fig"}), but ciliogenesis was not increased ([Figure 5f](#F5){ref-type="fig"}). Similarly, the level of endogenous Hh target genes, such as *Ptch1*, was also not increased ([Figure 5h](#F5){ref-type="fig"}). These data do not support INTU as a driver for ciliogenesis or Hh pathway activation. Thus, the elevated expression of *INTU* in human BCCs might be required but not sufficient for the development of tumors.

DISCUSSION {#S10}
==========

The ciliogenic functions of the CPLANE genes (*Fuz*, *Wdpcp*, and *Intu*) are indispensable during vertebrate morphogenesis ^[@R4]--[@R6],\ [@R20]--[@R25]^. The current study extended their biological functions to mammalian tumorigenesis by demonstrating that INTU plays a permissive role in BCC formation through regulating primary cilia formation and Hh signaling. Because that the CPLANEs form a molecular module by interacting physically to facilitate the assembly of the IFT-A complex during ciliogenesis ^[@R7]^, it is speculated that genetically disrupting other CPLANE genes may block BCC formation in a fashion similar to *Intu*.

The robust upregulation of *INTU* transcription in BCC cells was surprising. It is not only in concert with the idea that INTU is prerequisite for ciliogenesis, but also suggests that INTU is required for the propagation and maintenance of ciliated BCC cells. While we did not obtain evidence supporting a role of INTU in directly driving ciliogenesis or Hh signaling ([Figure 5g--h](#F5){ref-type="fig"}), it is of interest to know that the expression level of *INTU* correlates with those of Hh responsive genes and ciliogenesis in BCC specimens ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). These observations suggest that INTU acts in concert with other molecular events to promote ciliogenesis and Hh pathway activation in BCC.

It remains unknown how *INTU* is upregulated in BCC. It may be a mere reflection of the increased proportion of ciliated BCC cells that already express relatively high endogenous levels of *INTU*. It is also possible that the expression of oncogenic mutant Hh genes, such as *PTCH1*, *SMO* or *Gli2*, may drive *de novo* upregulation of *INTU*, and probably other ciliogenic genes, to deregulate the ciliogenic and retraction programs to favor cilia formation in keratinocytes. Another possible mechanism is UV, a primary risk factor for BCC ^[@R26]^ and a robust inducer of ciliogenesis ^[@R27]^. UV may exert previously unappreciated ciliogenic functions during the early stages of BCC formation. Understanding how *INTU* is upregulated may provide important insight into BCC tumorigenesis.

Previous observations suggested that very few interfollicular epidermal keratinocytes in adult skin possess a functional cilium, whereas BCC cells are frequently ciliated ^[@R6],\ [@R17],\ [@R28]^. Indeed, quantifications obtained in this study confirmed these findings, thereby suggest that primary cilium is a candidate biomarker for BCC. But it is unclear how BCC cells acquired the cilia phenotype. In addition to the altered intrinsic ciliogenic programs discussed above, it is also possible that BCC originates from the few ciliated keratinocytes. It is conceivable that ciliated keratinocytes can activate the Hh signaling pathway more readily upon acquiring Hh pathway mutations, thereby, may gain growth advantage over unciliated keratinocytes. Thus, these findings provided insight into the debated origin of BCC ^[@R18],\ [@R19],\ [@R29]--[@R32]^ by suggesting that BCC may be more readily established from ciliated keratinocytes in the skin and hair follicles. Collectively, evidence supports the idea that ciliated keratinocytes are prone, whereas unciliated keratinocytes are resistant, to malignant transformation of keratinocytes.

Activation of the Hh pathway, which is a major driver of BCC, is dependent upon the primary cilium. The primary cilium is critical for BCC formation as we and others demonstrated that preventing cilia assembly by genetically ablating ciliogenic genes, such as *Ift88*, *Kif3a*, and *Intu* prevented BCC (^[@R17]^ and this study) could block the development of BCC in mice. These findings suggest that ciliogenic proteins might be therapeutic targets for BCC. However, systemically targeting INTU and other ciliogenic proteins is likely to result in significant adverse effects on the normal ciliary functions, such as those in the retina, kidney, and other organs. Therefore, this strategy is unlikely worthwhile. In contrast, targeting SMO with small molecules is remarkably effective for locally advanced or metastatic BCCs ^[@R33]^. However, the development of treatment-resistant tumors in association with SMO inhibitor treatment ^[@R34]--[@R37]^ presses for the identification of new therapeutic targets along the Hh signaling pathway ^[@R38],\ [@R39]^. Thus, targeting Hh signaling components downstream of ciliogenesis and the smoothened receptor may become promising therapeutic strategies for BCC and other Hh-dependent cancers ^[@R40]--[@R42]^.

In summary, this study provided evidence that ciliogenic genes, such as *INTU*, are dynamically regulated in the skin, and that the upregulation of *INTU* is required but not sufficient for ciliogenesis and oncogenic Hh signaling during BCC formation. Understanding the molecular mechanism underlying with the aberrant upregulation of ciliogenic genes, such as *INTU*, during early stages of BCC formation may shed light on the prevention of BCC and other Hh-dependent tumors.

MATERIALS AND METHODS {#S11}
=====================

Skin and BCC specimens {#S12}
----------------------

Formalin-fixed and paraffin-embedded healthy adult human skin, BCC, and SCC specimens (n = 25) were obtained from the biobank of the Department of Pathology. All specimens were de-identified. The use of human specimens was approved by the Institutional Review Board of Stony Brook University. Tumor histology was confirmed and areas of interest were chosen by two pathologists (CL and KRS) before they were used for the construction of a tissue microarray (TMA). Two cores of each specimen were randomly placed in the TMA block. All the staining and analyses were performed using slides sectioned from the TMA. One BCC specimen was lost during this process and was excluded. The TMA was comprised of 3 healthy skins, 19 BCCs, and 3 SCCs.

Mouse models and tissue collection {#S13}
----------------------------------

The conditional mouse model of *Intu* (*Intu^flox/flox^*) were reported previously ^[@R5]^. Tg(KRT14-cre/ERT)20Efu/J and Gt(ROSA)26Sor^tm1(Smo/EYFP)Amc^/J (a conditional allele of Smo, also known as SmoM2^Cond^) mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Mice were bred to generate the bigenic or trigenic mice used in the study. Littermates were used as controls wherever possible. Both male and female mice were included in this study, and housed in groups of the same age and sex regardless of genotypes. Cre recombination was induced by tamoxifen (T5648, Sigma-Aldrich, St. Louis, MO) as described previously ^[@R18]^. Briefly, 2.5 mg tamoxifen (dissolved in sesame oil) was injected intraperitoneally to 22 -- 27 day old mice once daily for five days. BrdU labeling was performed by injecting 10 μg per gram of body weight of BrdU labeling reagent (Life Technologies, Waltham, MA) 2 hours prior to euthanasia. Injections were carried out blindly.

Based on our experience gained from a pilot study, we collected skin specimens from mice at two time points after tamoxifen induction. Additional time points were applied on *Intu*-deficient (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^*) mice up to 22 weeks after induction. We aimed to obtain a minimum of three mice for each time point. Freshly dissected dorsal skins were either frozen in optimal cutting temperature compound (Sakura Finetek USA, Torrance, CA) or fixed overnight in 10% buffered formalin and processed for routine histology. All procedures related to mice were approved by the IACUC of Stony Brook University.

Measuring the thickness of the epidermis {#S14}
----------------------------------------

Three randomly chosen fields of each H&E section were photographed with a 20X objectives, and the thickness of the interfollicular epidermis (IFE) was measured using Nikon (Melville, NY) NIS-Elements Analysis D software. The average epidermal thickness from each mouse was used for analysis. Specifically, n = 9 or 18 for *Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^* mice at 5 weeks or 10 weeks post induction, respectively; n = 9, 12, or 18 for *Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^* mice at 5, 10, or 22 weeks post induction.

Cell culture and *in vitro* assays {#S15}
----------------------------------

The isolation of primary mouse epidermal keratinocyte was conducted as described elsewhere ^[@R43]^. Briefly, skins of E18.5 embryos were digested by dispase II (Roche, Indianapolis, IN) to separate epidermis and dermis. Epidermis was then digested briefly with trypsin (Invitrogen) to dissociate keratinocytes. Keratinocytes were suspended in defined keratinocyte serum-free medium (Gibco, Life Technologies Waltham, MA) and plated on collagen I-coated tissue culture plates (Thermo Fisher, Waltham, MA). MEFs were cultured with Dulbecco's modified Eagle's medium (4.5 g/l glucose) supplemented with 10% fetal bovine serum and 100 U/ml penicillin and 100 U/ml streptomycin (Gibco, Life Technologies). To induce Cre recombination, subconfluent keratinocytes were treated with 0.5 μM 4-OH tamoxifen (Sigma-Aldrich) for 5 hours before grown to near-confluent, and starved in medium without growth supplement for 72 hours before harvested for RNA extraction or immunofluorescence. To activate Hh signaling, MEFs were grown to confluency and serum-starved in medium containing 0.25% serum for 24 hours, then treated with 400 nM smoothened agonist (SAG, Calbiochem, San Diego, CA) for 4.5 hours before harvested for mRNA extraction.

DNA constructs and transfection {#S16}
-------------------------------

Expression plasmid encoding *Intu*, full length mouse *Gli2* (Gli2-FL), and the constitutively active *Gli2* lacking the coding sequence for the first 413 amino acids (Gli2ΔN) were described previously ^[@R5],\ [@R44]^. GLI2 was expressed as a fusion protein with YFP. The transfections were carried out by Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA) per manufacturer's instructions.

Quantitative RT-PCR {#S17}
-------------------

RNA isolation and quantitative RT-PCR analyses were performed as previously described ^[@R6]^. The following TaqMan probes were used: *Ptch1*, Mm00436026_m1; *Gli1*, Mm00494645_m1; *Gli2,* Mm01293111_m1; *Intu*, Mm01284303_m1; and *β-actin*, Mm00607939_m1 (Life Technologies). Results were analyzed using the ΔΔCt method. Relative expression levels of target genes were normalized with β-actin and compared with controls.

*In situ* hybridization and scoring {#S18}
-----------------------------------

*In situ* hybridization was carried out on formalin-fixed paraffin embedded tissue sections using the RNAScope system (Advanced Cell Diagnostic, Inc, Hayward, CA) per manufacturer's instructions. The probes used are *INTU* (413571), *GLI1* (310991), *PTCH1* (405781), *SMO* (405831), *Intu* (413601), *Gli1* (311001), and *Ptch1* (402811).

Semi-quantitative scoring was performed for signaling generated by each target probe on all TMA specimens. Scoring was based on the average number of signal puncta within a cell's boundary. *POLR2A* (Cat 310451) was used as an internal positive control for the quality of each specimen for this assay. Scores of each target probe were then normalized by *POLR2A*. Normalized scores of the randomly placed cores of the same specimen were averaged and presented. Scoring was performed by the investigators blind to the protocol.

Immunofluorescence labeling and microscopy {#S19}
------------------------------------------

Immunofluorescence labeling was performed as described previously ^[@R6]^. The following primary antibodies were used: antibody to KRT1 was produced in the Roop lab^[@R45]^; KRT14 (Covance; Princeton, NJ); GFP/YFP (Aves Labs Inc; Tigard, Oregon); KRT17 (Abcam, Cambridge, MA, USA); LEF1 (Cell Signaling, Danvers, MA); BrdU (Life Technologies); acetylated α-tubulin (Sigma); γ-tubulin (Abcam, Cambridge, MA), ARL13B (NeuroMab, 73-287; Davis, CA); AlexaFluor-conjugated secondary antibodies were from Life Technologies. Mounting medium with DAPI (Vector Laboratories, Burlingame, CA) was used. Images were acquired by Nikon 80*i* fitted with Nikon DS-Qi1Mc camera and processed with Photoshop 5.5 CS.

Statistical analyses {#S20}
--------------------

All quantifications are presented as mean ± SD. Student t-test (two-tail, unpaired, assuming unequal variance) was used unless otherwise stated. Kaplan-Meier curve, one-way ANOVA, two-way ANOVA analyses were generated by the GraphPad software (GraphPad Software, Inc., San Diego, CA). *P* \< 0.05 is considered statistically significant.
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![*INTU*, Hh signaling, and primary cilia in healthy skin, BCC, and SCC. (**a**) Representative H&E staining and *in situ* hybridization of *INTU*, *PTCH1, GLI1*, and *SMO* in healthy adult human skin (normal skin), BCC, and SCC. (**b** -- **e**) Normalized scores of signal intensity of *in situ* hybridization in (a). (**f**) Representative images of primary cilia (ARL13B, green) and basal body (γ-tubulin (TUB), red) in normal skin, BCC, and SCC. Nuclei were stained with DAPI (blue). Lower panels are enlarged boxed areas above. (**g**) Percentage of ciliated keratinocytes in specimens in (f). n = 3 for normal adult skin or SCC, n = 19 for BCC. \*, *P* \< 0.05; \*\*\*, *P* \< 0.001, two-way ANOVA and pair-wise posttest. Scale bar = 25 μm.](nihms862755f1){#F1}

![Disrupting *Intu* blocks BCC formation in mice. (**a**) Disease-free survival of *SmoM2*-driven BCC mouse models. Control, *Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^* (n=9); homozygous *Intu* mutants, *Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^* (n = 14). \*\*\*, *P* \< 0.0001, Logrank test. (**b**) Representative gross appearance (upper panels) and H&E staining (lower panels) of the dorsal skin harvested 10 weeks after tamoxifen induction. Arrow points to a focal epidermal invagination. (**c**) Immunofluorescence images of YFP (green) in dorsal skin of control and homozygous mouse models in (B). KRT14 was labeled red. Nuclei stained with DAPI (blue). (**d**) Thickness of interfollicular epidermis (IFE) of specimens in (B). Mean ± SD. \*\*\*, *P* \< 0.001, posttest, two-way ANOVA. (**e**) Percentage of BrdU and KRT14 double positive cells in specimens in (B). Mean ± SD. \*\*\*, *P* \< 0.001, T-Test. Scale bar = 50 μm.](nihms862755f2){#F2}

![Primary cilia, Hh and Wnt signaling in BCC mouse models. (**a**) Immunofluorescence labeling of primary cilia (ARL13B, green) and basal body (γ-tubulin (TUB), red) in dorsal skin of control (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^*, n = 4, and homozygous (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^*, n = 4) BCC mouse models and control mice (*Krt14-Cre^ERT^;Intu^+/flox^*, n = 3), and quantification of ciliated keratinocytes. A minimum of 150 keratinocytes were evaluated per mouse. \*\*\*, *P* \< 0.001, two-way ANOVA and pair-wise posttest. Nuclei were stained with DAPI (blue). (**b**) *In situ* hybridization of *Gli1* and *Ptch1* in dorsal skin obtained from specimens in (**a**). (**c**) Immunofluorescence labeling of LEF1 (red) in dorsal skins obtained from specimens in (**a**). Keratinocytes were labeled with KRT14 (green). Nuclei were staining with DAPI (blue). Lower panels are enlarged boxed areas above. Scale bar = 25 μm.](nihms862755f3){#F3}

![Hh signaling and primary cilia in primary epidermal keratinocytes expressing *SmoM2*. (**a**) Relative transcription levels of *Gli1* and *Intu* in primary keratinocytes treated with 4-OH tamoxifen. n=3, \*, *P* \< 0.05, one-way ANOVA and posttest. (**b**) Representative immunofluorescence labeling of YFP (green) and primary cilia (acetylated α-tubulin (TUB), red, and ARL13B, blue) in 4-OH tamoxifen induced keratinocytes isolated from control (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^+/flox^*) and homozygous (*Krt14-Cre^ERT^;SmoM2^cond^;Intu^flox/flox^*) mouse models. n = 3 per genotype. Arrowhead points to a triple positive cilium in an induced cell; arrow points to a cilium in an uninduced cell. (**c**) Statistical analysis of ciliated cells based on the expression of YFP as shown in (**b**).](nihms862755f4){#F4}

![Effects of the expression levels of *Intu* on ciliogenesis and Hh signaling. (**a**) Primary cilia (ARL13B, green) and basal body (γ-tubulin, red) in wild type (WT) and *Intu^−/−^* mouse embryonic fibroblasts (MEFs). (**b**) The relative expression levels of full-length GLI3 (GLI3-FL) and GLI3 repressor (GLI3-R) in DMSO and SAG-treated WT and *Intu^−/−^* MEFs, and quantification (right). n = 3. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001, two-way ANOVA and pair-wise post analysis. (**c** -- **e**) Expression of *Gli1* (**c**), *Ptch1* (**d**), and *Gli2* (**e**) in WT and *Intu^−/−^* MEFs in response to the overexpression of full-length *Gli2* (Gli2-FL) and a constitutively active *Gli2* (Gli2ΔN), and SAG in a representative experiment. Vehicle (V) treated cells were used as controls. n = 4. (**f**) Primary cilia (ARL13B, green) in WT MEFs transfected with mouse *Intu*-GFP cDNA (*mIntu*), and quantification (right). (**g** -- **h**) Relative expression levels of *Intu* and *Ptch1* in *mIntu*-transfected MEFs. Mock transfected cells were used as controls. n = 4. Scale bar = 10 μm.](nihms862755f5){#F5}
